Ultragenyx Lost Nearly Half Its Value Overnight. Now a Review Begins.
The Angelman trial missed both endpoints, cost cuts loom, and an FDA decision is 16 days away.
September 3, 2026
Congress Cleared the Shutdown. Dec. 11 Is the New Risk.
The 370-48 House vote removes the Sept. 30 cliff, keeps the data calendar intact, and hands traders a fresh deadline…